N. Muirhead

发表

A study of the quality of life and cost-utility of renal transplantation.

A. Laupacis, H. Krueger, P. Keown, 1996, Kidney international.

Clinical practice guidelines for the management of anemia coexistent with chronic renal failure

P. Halligan, E. Toffelmire, W. McCready, 1999 .

Disease-specific questionnaire for patients with a renal transplant.

A. Laupacis, P. Keown, N. Pus, 1993, Nephron.

Kidney and liver transplants from donors after cardiac death: initial experience at the London Health Sciences Centre.

A. House, A. Jevnikar, Vivian Charles McAlister, 2010, Canadian journal of surgery. Journal canadien de chirurgie.

Randomized open‐label crossover assessment of Prograf vs Advagraf on immunosuppressant pharmacokinetics and pharmacodynamics in simultaneous pancreas‐kidney patients

N. Muirhead, M. Knauer, P. Luke, 2018, Clinical transplantation.

Fate of the Mate: The Influence of Delayed Graft Function in Renal Transplantation on the Mate Recipient

A. House, A. Jevnikar, J. Mahon, 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Update in Nephrology

N. Muirhead, 2010, Annals of Internal Medicine.

Canadian survey of clinical status at dialysis initiation 1998-1999: a multicenter prospective survey.

A. Levin, B. Culleton, C. Clase, 2002, Clinical nephrology.

Sexual and Endocrine Function in Uraemia

N. Muirhead, 1988 .

Management of anemia.

N. Muirhead, U. Buoncristiani, M. Rao, 2004, Contributions to nephrology.

Predictors of Erythropoietin Responsiveness in Chronic Hemodialysis Patients

M. Tonelli, P. Blake, N. Muirhead, 2001, ASAIO journal.

A disease-specific questionnaire for assessing quality of life in patients on hemodialysis.

A. Laupacis, P. Keown, C. Wong, 1992, Nephron.

The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation--study design.

D. Holland, G. Knoll, B. Kiberd, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

An operating cost comparison between conventional and home quotidian hemodialysis.

W. Clark, A. P. Heidenheim, R. Lindsay, 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Patient quality of life on quotidian hemodialysis.

L. Moist, A. P. Heidenheim, R. Lindsay, 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada.

R. Goeree, A. Laupacis, N. Muirhead, 1992, Social science & medicine.

Supramaximal dose of candesartan in proteinuric renal disease.

E. Burgess, S. Tobe, N. Muirhead, 2009, Journal of the American Society of Nephrology : JASN.

The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial

N. Rodger, J. Mahon, N. Muirhead, 1999 .

Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.

Christine A. White, D. Holland, G. Knoll, 2016, The lancet. Diabetes & endocrinology.

Effect of valsartan on urinary protein excretion and renal function in patients with chronic renal allograft nephropathy.

A. House, A. Jevnikar, N. Muirhead, 2003, Transplantation proceedings.

The rationale for early management of chronic renal insufficiency.

N. Muirhead, 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Chronic kidney disease: why is current management uncoordinated and suboptimal?

E. Ritz, T. Golper, F. Valderrábano, 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

IgA nephropathy is not a rare disease in the United Kingdom.

D. Power, N. Muirhead, N. Edward, 1985, Nephron.

Management of idiopathic membranous nephropathy: evidence-based recommendations.

N. Muirhead, 1999, Kidney international. Supplement.

Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction.

D. Cattran, P. Keown, K. Jindal, 1994, Journal of the American Society of Nephrology : JASN.

Evidence-based recommendations for the clinical use of recombinant human erythropoietin.

A. Levin, P. Parfrey, J. Bargman, 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Individualizing anaemia treatment: a discussion of case histories.

N. Muirhead, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

THE EFFECT OF VALSARTAN AND CAPTOPRIL ON LIPID PARAMETERS IN PATIENTS WITH TYPE II DIABETES MELLITUS AND NEPHROPATHY

N. Rodger, R. Lewanczuk, N. Muirhead, 1999, International journal of clinical practice.

Occult infection and resistance of anaemia to rHuEpo therapy in renal failure.

N. Muirhead, A. Hodsman, 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients.

N. Muirhead, A. Hodsman, D. Hollomby, 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.

D. Churchill, C. Wong, N. Muirhead, 1992, American journal of nephrology.

In reply to 'A perspective from the Baltics regarding the Canadian Society of Nephrology commentary on the KDIGO Glomerulonephritis Guideline'.

N. Muirhead, 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Management of anemia with quotidian hemodialysis.

S. Klarenbach, L. Moist, R. Lindsay, 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Suppression of secondary hyperparathyroidism in uraemia: acute and chronic studies.

S. Adami, N. Muirhead, J. O'riordan, 1984, British medical journal.

Zinc metabolism in patients on maintenance hemodialysis.

N. Muirhead, A. Hodsman, P. Flanagan, 1986, American journal of nephrology.

Loin pain and haematuria in young women: diagnostic pitfalls.

N. Muirhead, J. Simpson, A. Nicholls, 1982, British journal of urology.

Secondary hyperparathyroidism complicated by parathyromatosis.

C. Stehman-Breen, D. Sherrard, N. Muirhead, 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

A. Villaflor, M. Pfeffer, C. Held, 2021, European heart journal.

Using dalteparin in quotidian and nocturnal hemodialysis patients: A prospective study

F. Rehman, S. Huang, R. Lindsay, 2019, Hemodialysis international. International Symposium on Home Hemodialysis.

Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection.

J. Rochon, A. Jevnikar, C. Stiller, 1993, Journal of immunology.

Erythropoietin and renal transplantation.

N. Muirhead, 1999, Kidney international. Supplement.

THE OUTCOME OF PREGNANCY FOLLOWING RENAL TRANSPLANTATION—THE EXPERIENCE OF A SINGLE CENTER

M. Rieder, N. Muirhead, A. Lazarovits, 1992, Transplantation.

Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children.

A. Humar, J. Bargman, G. Knoll, 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Factors Affecting the Response to Erythropoietin in Chronic Renal Failure

N. Muirhead, 1991 .

Recombinant human erythropoietin: factors to consider in cost-benefit analysis.

A. Laupacis, N. Muirhead, D. Churchill, 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice

J. Gill, N. Muirhead, D. Churchill, 2014, Clinical transplantation.

Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.

A. Jevnikar, K. McLaughlin, N. Muirhead, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

CONTROL OF SECRETION OF PARATHYROID HORMONE IN SECONDARY HYPERPARATHYROIDISM

S. Adami, N. Muirhead, S. Papapoulos, 1982, Clinical endocrinology.

Metabolic consequences of bilateral nephrectomy.

N. Muirhead, G. Catto, 1984, British medical journal.

Comparative hospitalization of hemodialysis and peritoneal dialysis patients in Canada.

A. Levin, R. Foley, P. Parfrey, 2000, Kidney international.

A rationale for an individualized haemoglobin target.

N. Muirhead, 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Acute glomerular thrombosis with CsA treatment.

P. Keown, N. Muirhead, D. Hollomby, 1987, Renal failure.

Recombinant human erythropoietin patient dosing algorithm.

N. Muirhead, 1990, Seminars in nephrology.

Re-exposure to Mismatched HLA Class I Is a Significant Risk Factor for Graft Loss: Multivariable Analysis of 259 Kidney Retransplants

F. Rehman, A. House, A. Jevnikar, 2007, Transplantation.

Effect of anaemia correction on skeletal muscle metabolism in patients with end-stage renal disease: 31P magnetic resonance spectroscopy assessment.

R. T. Thompson, G. Marsh, A. Driedger, 1996, Nephron.

Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection.

J. Rochon, A. Jevnikar, C. Stiller, 1993, Transplantation proceedings.

Erythropoietin Dose Requirements When Converting from Subcutaneous to Intravenous Administration Among Patients on Hemodialysis

L. Moist, A. House, Kerri Gallo, 2006, The Annals of pharmacotherapy.

Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Nephrology.

P. Halligan, W. McCready, S. Fenton, 1999, Journal of the American Society of Nephrology : JASN.

Cyclosporine Microemulsion (Neoral®) Absorption Profiling and Sparse‐sample Predictors During the First 3 Months after Renal Transplantation

J. Wauters, R. Balshaw, P. Keown, 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group.

D. Rush, P. Parfrey, R. Loertscher, 1996, Transplantation.

Erythropoietin Is a Cause of Access Thrombosis

N. Muirhead, 1993 .

Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients1

V. Shahinian, A. House, A. Jevnikar, 2003 .

Cytomegalovirus seromismatching increases the risk of acute renal allograft rejection.

A. Jevnikar, N. Muirhead, Gordon Fick, 2002, Transplantation.

Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients.

F. Rehman, A. House, A. Şener, 2006, Transplantation.

Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients.

D. Churchill, D. Taylor, W. Fay, 1995, Clinical nephrology.

Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients.

V. Shahinian, A. House, A. Jevnikar, 2003, Transplantation.

Proteinuria and reduced kidney function in living kidney donors: A systematic review, meta-analysis, and meta-regression.

A. Garg, R. C. Yang, M. Rosas-Arellano, 2006, Kidney international.

Meta-Analysis: Risk for Hypertension in Living Kidney Donors

A. Garg, M. Rosas-Arellano, G. Knoll, 2006, Annals of Internal Medicine.

A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.

G. Remuzzi, R. Walker, J. Buckels, 1996, Transplantation.

Ultrafiltration studies in vitro of serum aluminum in dialysis patients after deferoxamine chelation therapy.

N. Muirhead, A. Hodsman, A. Henderson, 1985, Clinical chemistry.

Patient Survival Following Renal Transplant Failure in Canada

G. Knoll, N. Muirhead, L. Trpeski, 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Randomized, International Study of Cyclosporine Microemulsion Absorption Profiling in Renal Transplantation with Basiliximab Immunoprophylaxis

G. Knoll, J. Wauters, R. Balshaw, 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of glomerulonephritis in adults.

A. Humar, J. Bargman, G. Knoll, 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

S. Huang, A. Vinks, A. Jevnikar, 2014, Therapeutic drug monitoring.

AIDS to Fluid And Electrolyte Balance

N. Muirhead, G. Catto, 1987 .

The impact of allograft nephrectomy on percent panel reactive antibody and clinical outcome.

V. Shahinian, A. House, A. Jevnikar, 2003, Transplantation proceedings.

Plasma exchange in acute renal allograft rejection: is a controlled trial really necessary?

D. Power, A. Macleod, N. Muirhead, 1981, Transplantation.

Removal of aluminum during hemodialysis: effect of different dialyzer membranes.

P. Keown, C. Stiller, N. Muirhead, 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection: analysis beyond 4 years.

N. Muirhead, A. Lazarovits, L. C. Sharma, 1997, Transplantation proceedings.

The Canadian Society of Nephrology methods in developing and adapting clinical practice guidelines: a review

A. Levin, P. McFarlane, N. Pannu, 2014, Canadian journal of kidney health and disease.

Transplant professionals vary in the long-term medical risks they communicate to potential living kidney donors: an international survey.

A. Garg, F. Rehman, C. Parikh, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT)

O. Djurdjev, A. Levin, C. Clase, 2013, BMC Nephrology.

Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD.

J. Singer, O. Djurdjev, A. Levin, 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

The Clinical Impact of Recombinant Human Erythropoietin

N. Muirhead, 1997, Journal of the Royal College of Physicians of London.

Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort.

O. Djurdjev, A. Levin, C. Clase, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Comparative mortality of hemodialysis and peritoneal dialysis in Canada.

A. Levin, R. Foley, P. Parfrey, 2000, Kidney international.

Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group).

A. Laupacis, C. Wong, N. Muirhead, 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Apparent low absorbers of cyclosporine microemulsion have higher requirements for tacrolimus in renal transplantation

F. Rehman, A. House, A. Jevnikar, 2007, Clinical transplantation.

Use of bone char as an adsorbent in preparation of water for dialysis.

N. Muirhead, R. Mitton, 1992, ASAIO journal (1992).

The Long‐Term Quality of Life of Living Kidney Donors: A Multicenter Cohort Study

A. Garg, M. Dew, S. Klarenbach, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Zinc metabolism does not influence sexual function in chronic renal insufficiency.

D. Kerr, N. Muirhead, R. Rodger, 1984, Contributions to nephrology.

Long-term effects of 1,25-dihydroxy vitamin D3 and 24,25-dihydroxy vitamin D3 in renal osteodystrophy.

S. Adami, N. Muirhead, J. O'riordan, 1982, The Quarterly journal of medicine.

Use of a Pelvic Kidney for Living Transplantation: Case Report and Review of the Literature

A. House, A. Jevnikar, Vivian Charles McAlister, 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events.

O. Djurdjev, A. Levin, R. Kim, 2016, Kidney international.

Fish oil in lupus nephritis: clinical findings and methodological implications.

C. Naylor, W. Clark, B. Holub, 1993, Kidney international.

The experience of living kidney donors.

A. Garg, J. Brown, N. Muirhead, 2008, Health & social work.

Living Kidney Donors' Experiences with the Health Care System

A. Garg, J. Brown, N. Muirhead, 2008, Social work in health care.

Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin.

D. Churchill, D. Taylor, W. Fay, 1994, Journal of the American Society of Nephrology : JASN.

Erythropoietic Agents in Peritoneal Dialysis

N. Muirhead, 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

Managing anemia. What do we do now? Views from Canada.

B. Manns, N. Muirhead, D. Mendelssohn, 2007, Nephrology news & issues.

Transfusion Management of Incident Dialysis Patients in Canada: A Prospective Observational Study

A. Bello, D. Churchill, N. Muirhead, 2018, Canadian journal of kidney health and disease.

Dialysis patients treated with Epoetin α show improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trial

D. Churchill, T. Mayne, P. Keown, 2011, Hemodialysis international. International Symposium on Home Hemodialysis.

Idiopathic thrombocytopenia after cytomegalovirus infection in a renal transplant recipient.

A. Jevnikar, M. Cruickshank, N. Muirhead, 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation.

A. Garg, S. Klarenbach, G. Knoll, 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group.

R. Loertscher, D. Landsberg, P. Keown, 1998, Transplantation.

SAFETY AND TOLERABILITY OF CYCLOSPORINE AND CYCLOSPORINE MICROEMULSION DURING 18 MONTHS OF FOLLOW-UP IN STABLE RENAL TRANSPLANT RECIPIENTS

Lisa Anne Hendricks, Nova Scotia, R. Loertscher, 1998 .

A comparison between cyclosporine and tacrolimus-based immunosuppression for renal allografts: renal function and blood pressure after 5 years.

A. House, A. Jevnikar, N. Muirhead, 2003, Transplantation proceedings.

Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults With Chronic Kidney Disease: The CKD WIT Randomized Clinical Trial

A. Garg, M. Weir, S. Pandeya, 2018, JAMA.

Prediction of early death in end-stage renal disease patients starting dialysis.

Henry Mandin, Marc B. Goldstein, Janet Morgan, 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Proteinuria and reduced kidney function in living kidney donors: A systematic review, meta-analysis, and meta-regression.

A. Garg, R. C. Yang, M. Rosas-Arellano, 2006, Kidney international.

Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.

S. Adami, N. Muirhead, S. Papapoulos, 1980, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study)

N. Pannu, J. Orazem, S. Soroka, 2018, Canadian journal of kidney health and disease.

Intermittent versus continuous renal replacement therapy for acute renal failure in adults.

A. Macleod, N. Muirhead, K. Rabindranath, 2007, The Cochrane database of systematic reviews.

Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy.

A. Levin, R. Foley, P. Parfrey, 2000, Kidney international.

Access type as a predictor of dialysis adequacy in chronic hemodialysis patients.

N. Muirhead, M. Tonelli, 2000, ASAIO journal.

Canadian Hemodialysis Morbidity Study.

D. Churchill, D. Taylor, P. Parfrey, 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

B Cells and Kidney Transplantation: Beyond Antibodies

B. Kasiske, P. Fauchald, A. Matas, 2014 .

Perceptions of prognostic risks in chronic kidney disease: a national survey

N. Tangri, O. Djurdjev, A. Levin, 2015, Canadian journal of kidney health and disease.

Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort.

O. Djurdjev, C. Clase, C. Rigatto, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Costs of Quotidian Home Hemodialysis

W. Clark, R. Lindsay, N. Muirhead, 2003 .

Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.

D. Coyle, R. Rodby, S. Soroka, 2007, Clinical therapeutics.